The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy.
 
Margaret T. Kasner
Consulting or Advisory Role - Amgen
Research Funding - Acorda Therapeutics (I); Amgen; Astellas Oncology; AstraZeneca (I); Bayer (I); Bristol-Myers Squibb (I); Daiichi Sankyo; GORE (I); Pfizer
 
Ellen K. Ritchie
Consulting or Advisory Role - Celgene; Incyte; Novartis; Pfizer
Speakers' Bureau - ARIAD; Celgene; Incyte; Novartis
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); NS Pharma (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Celgene; Novartis
 
David Cutler
Employment - Athenex; Athenex (I)
Stock and Other Ownership Interests - Athenex; Merck
 
Gerald J. Fetterly
Employment - Athenex
 
Douglas Kramer
Employment - Athenex
 
David Hangauer
Employment - Athenex
 
James E. Thompson
No Relationships to Disclose